The Oncology Institute (NASDAQ: TOI) updates 2025 guidance and 2026 outlook

Rhea-AI Filing Summary

The Oncology Institute, Inc. reported that it has issued a press release reaffirming its 2025 financial guidance and providing a preliminary financial outlook for 2026, along with additional longer-term financial guidance. The press release is included as Exhibit 99.1 to this report and is incorporated by reference.

The company states that the information under Item 2.02, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.

false 0001799191 0001799191 2026-01-12 2026-01-12 0001799191 TOI:CommonStockParValue0.0001Member 2026-01-12 2026-01-12 0001799191 TOI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockEachAtExercisePriceOf11.50PerShareMember 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

Form 8-K

__________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  January 12, 2026

___________________________________

THE ONCOLOGY INSTITUTE, INC.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware		001-39248		84-3562323
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

18000 Studebaker Road, Suite 800, Cerritos, CA		90703
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:  (562) 735-3226

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001		TOI		The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of $11.50 per share		TOIIW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.

Item 2.02. Results of Operations and Financial Condition.

On January 12, 2026, The Oncology Institute, Inc. (the “Company”) issued a press release reaffirming the Company’s 2025 financial guidance and providing the Company’s preliminary 2026 financial outlook and certain additional longer-term financial guidance. A copy of the press release is furnished hereto as Exhibit 99.1, which is incorporated by reference herein.

The information contained in this Item 2.02, including Exhibit 99.1, is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits 

Exhibit No.		Description
99.1		Press Release issued by The Oncology Institute, Inc., on January 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 12, 2026	THE ONCOLOGY INSTITUTE, INC.
	By:	/s/ Mark Hueppelsheuser
		Mark Hueppelsheuser
		General Counsel

FAQ

What did The Oncology Institute (TOI) disclose in this 8-K?

The Oncology Institute, Inc. disclosed that it issued a press release reaffirming its 2025 financial guidance and providing preliminary 2026 and longer-term financial guidance, furnished as Exhibit 99.1.

Where can investors find the detailed TOI 2025 guidance and 2026 outlook figures?

Detailed figures and targets are contained in the press release attached as Exhibit 99.1 to this report, which is incorporated by reference.

Is the TOI guidance information considered filed or furnished with the SEC?

The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act.

What is Exhibit 99.1 in The Oncology Institute (TOI) 8-K?

Exhibit 99.1 is a press release issued by The Oncology Institute, Inc. on January 12, 2026, covering reaffirmed 2025 guidance, preliminary 2026 outlook, and longer-term financial guidance.

Does this TOI 8-K include historical financial results?

The report focuses on reaffirmed 2025 financial guidance, preliminary 2026 outlook, and longer-term guidance via the Exhibit 99.1 press release, rather than historical financial results.